Posters & Abstracts
We would like to thank Red Maple Trials (RMT), staff at Yang Medicine, the HAE Canada Advocacy Committee and Board of Directors, as well as HAE specialists from across Canada for the amazing job they do creating our posters and abstracts. We are grateful we can collaborate with this team of experts. These documents are developed using real world data collected from our members through our different surveys, particularly our two National Report Card surveys (2017 & 2020). Thank you to our members who complete our surveys; we are grateful to have an engaged membership.
Please click the images to view the posters and abstracts that HAE Canada presented at both national and international scientific meetings.
2023
American Academy of Allergy Asthma and Immunology (AAAAi)’s Annual Meeting in San Antonio, Texas (February)
Emergency room visits by patients with HAE based on data from the Canadian 2020 national survey
2022
HAE International 2022 Global Leadership Workshop, in Frankfurt, Germany (October)
HAE with normal C1 esterase inhibitor (HAEnC1INH): Diagnosis, treatment and attack frequency from the 2020 Canadian patient survey
Canadian Society of Allergy and Clinical Immunology (CSACI) Annual Scientific Meeting, in Quebec City (September)
HAE with normal C1 esterase inhibitor (HAEnC1INH): Treatment and attack frequency changes from 2017 to 2020 based on data from the Canadian national patient surveys
European Academy of Allergy and Clinical Immunology (EAACI)‘s Hybrid Congress in Prague, Czech Republic (July)
Type I/II HAE: Treatment and attack frequency improvements between 2017 and 2020 based on data from the Canadian national patient surveys
American Academy of Allergy Asthma and Immunology (AAAAi)’s Virtual Annual Meeting in Phoenix, AZ (February)
HAE with Normal C1-INH: treatment and attack frequency based on data from the Canadian 2020 National Report Card survey
2021
Canadian Society of Allergy and Clinical Immunology (CSACI)‘s Virtual Scientific Meeting (September)
HAE in Canada: Changes in medication use and untreated attacks between 2017 and 2020 surveys.
European Academy of Allergy and Clinical Immunology (EAACI)‘s Hybrid Congress in Madrid & Krakow (July)
HAE in Canada: Preliminary demographic and treatment results from the second national survey
AAAAi’s Virtual Annual Meeting (February)
Real World Data of Canadians living with angioedema: Health Economic Burden
2020
Japanese Society of Allergology (JSA) / World Allergy Organization (WAO) Joint Congress 2020 (October) *
Assessment of HAE-specific quality of life and proximity to acute therapy &
Prodromes and attack triggers in Canadian HAE patients
EAACI Digital Congress (June) **
Real world data of Canadians living with HAE: Need for innovative, newer prophylactic and subcutaneous medications
HAE International (HAEi)’s HAE Global Virtual Conference (May)
Fear of Attacks Reduces Quality of Life for Canadian HAE Patients
* in collaboration with the Canadian HAE Network (CHAEN)
** This poster was awarded a Five Star Rating by Dr. Marcus Maurer at the EAACI Digital Congress
2019
CSACI’s Scientific Meeting in Montreal (September)
Real World Data of Canadians living with HAE: Attributes of new medications.
Takeda’s HAE Global Forum in Berlin, Germany (September)
Real World Data of Canadians living with HAE: Attributes of new medications
2018 & 2019
Developed using data from our 2017 National Report Card survey, these four posters were presented at:
CSL Behring‘s 40th Anniversary for C1 inhibitor conference in Marburg, Germany (August 2019)
European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal (June 2019)
American Academy of Allergy, Asthma & Immunology (AAAAi)’s Annual Meeting in San Fransisco (February 2019)
Canadian Society of Allergy and Clinical Immunology (CSACI)’s Annual Scientific Meeting in Halifax (September 2018)
HAE International (HAEi)’s Global Conference in Vienna, Austria (May 2018)
Real World Data of Canadian Adults Living with HAE Part 1: Demographics
Real World Data of Canadian Adults living with HAE Part 3: Treatment Utilization
Real World Data of Canadian Adults Living with HAE Part 2: Attack Profile
Real World Data of Canadian Adults living with HAE Part 4: Treatment Satisfaction